San Francisco has confirmed its first case of a more severe strain of mpox, and before the panic cycle kicks into high gear, let's talk about what this actually means.

The city's public health apparatus is no stranger to infectious disease scares. We lived through COVID. We watched monkeypox sweep through the city in 2022. And each time, the same pattern emerged: alarm, followed by a messy government response heavy on press conferences and light on actionable strategy, followed by the quiet realization that targeted, common-sense measures work better than sweeping mandates.

So here we are again. A more severe mpox strain has arrived in San Francisco. The key questions taxpayers should be asking aren't just medical — they're fiscal and structural. How prepared is the Department of Public Health? Have we actually learned anything from the last go-round, or did the millions we poured into pandemic infrastructure evaporate into the usual bureaucratic fog?

Let's be clear: this isn't a call to ignore the situation. Severe strains deserve serious attention, and residents who are at higher risk should absolutely stay informed and consult their doctors. Public health matters — that's not up for debate.

But what is up for debate is whether San Francisco's leadership can respond proportionally. This city has a habit of either ignoring problems until they're unmanageable or overreacting in ways that cost a fortune and accomplish little. There's a sweet spot between indifference and hysteria, and City Hall has historically struggled to find it.

What we'd like to see: transparent data reporting from day one, clear guidance on who is most at risk, efficient allocation of vaccines and treatments to those who need them, and — this is the big one — no mission creep. Fund what works. Skip the virtue-signaling task forces.

One confirmed case is not an epidemic. But it is a test. And given SF's track record, we'll be watching closely to see if our public health dollars are actually buying competence this time around.